Drug Evaluation: Anti-infectives: Saquinavir: A review of its development, pharmacological properties and clinical use

References

• WEI X, GHOSII SK, TAYLOR ME, PION VA, EMINI EA, DEUTSCH P. LIFSON JO, BONHOEFFER S. NOWAK MA, HAHN BII, SAAG MS, SHAW GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 373:117–122.
   PubMed Web of Science ®Google Scholar
• HO DD, NEUMANN AU, PERELSONAS, CI IEN W, LEONARD JM, 1VIARKOWITZ M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 373:123–126
   PubMed Web of Science ®Google Scholar
• COFFIN JM: HIV population dynamics in vivo: implica- tions for genetic variation, pathogenesis and therapy. Science (1995) 267:483–489.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Resistance to antiretroviral compounds: implications for the clinical management of NW infec-tion. Immunot Infect. Dis. (1995) 5:170-182. Up-to-date review of antiretroviral resistance.
   Google Scholar
• STEVENSON M, BUKRINSKY M, HAGGERTY S: HIV-1 rep-lication and potential targets for intervention. AIDS Res. Hum. Retroviruses (1992) 8:107–117.
   PubMed Web of Science ®Google Scholar
• KATZ RS, SKALKA AM: The retroviral enzymes. Ann. Rev.Biochem. (1994) 63:133–173.
   PubMed Web of Science ®Google Scholar
• HUNTER E: Macromolecular interactions in the assem-bly of IIIV and other retroviruses. Semin. Virol. (1994) 5:71–83.
   Google Scholar
• NA VIA M, MCKEEVER BM: A role for the aspartyl proteasefrom the human immunodeficiency virus type-1 1) in the orchestration of virus assembly. Ann. NY Acad. Sci. (1990) 616:73–85.
   PubMed Web of Science ®Google Scholar
• KRAMER RA, SCHABER MD, SKALKA AM, GANGULY K,WONG-STAAL F, REDDY EP: HTLV-111 gag protein is processed in yeast cells by the virus pol-protease. Sci-ence (1986) 231:1580–1584.
   PubMed Web of Science ®Google Scholar
• KOHL NE, EMINI EA, SCHLEIF WA, DAVIS g, HEIMBACH JC, DIXON RA, SCOLNICK EM, SIGAL IS: Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686-4690. Important 'proof of concept' data.
   Google Scholar
• PETTIT SC, MICHAEL SF, SWANSTROM R: The specificity of HIV-1 proteinase. Perspect. Drug Discov. Des. (1993) 1:69–83.
   Google Scholar
• HENDERSON LE, COPELAND TD, SOWDER RC, SCHULTZAM, OROSZLAN S: Analysis of proteins and peptides from sucrose gradient banded HTLV-111. In: Human Retroviruses, Cancer and AIDS. Bologsesi D (Ed.), Liss, New York (1989):135–147.
   Google Scholar
• ROBERTS NA, MARTIN JA, KINCHINGTON D, BROAD-00HL'RST AV, CRAIG JC, DUNCAN IB, GALPIN SA, HANDA BK, KAY J, KROHN A: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 248:358-361. Review of initial chemistry and antiviral data which led to the choice of saquinavir for future development.
   Google Scholar
• SZELKE M: Chemistry of renin inhibitors. In: Aspartic Proteinases and their Inhibitors. Koska V (Ed.), De Gruyter, Berlin, New York (1985):421–441.
   Google Scholar
• BROADHURST AV, ROBERTS NA, RICHIE AJ, IIANDA BK,KAY C: Assay of HIV-1 proteinase: a colorimetric method using small peptide substrates. Anal. Biochem. (1991) 193:280–286.
   PubMed Web of Science ®Google Scholar
• MARTIN JA: Ro 31-8959/003. Drugs Future (1991) 16:210–212.
   Google Scholar
• KLABE RM. MEEK _IL: HIV protease inttgAtion: compari- son of Ks for XM323, Ro 31–8959, and A-80897. 33rd ICAAC New Orleans (1993). Abstract
   Google Scholar
• REDS1LAW 5, Inhibitors of HIV proteinase. Exp. Opin. Invest. Drugs (1994) 3:273–286.
   Google Scholar
• ROBERTS NA, CRAIG JC. DUNCAN IB: IIW proteinase inhibitors. Biochem. Soc. Trans.( I 992) 20:513–516.
   Google Scholar
• CRAIG JC, DUNCAN IB, HOCKLEY D, GRIEF C, ROBERTSNA, MILLS JS: Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) pro-teinase. Antiviral Res. (1991) 16:295–305.
   PubMed Web of Science ®Google Scholar
• CRAIG JC. GRIEF C, MILLS JS et al.: Anti-111V activity of aspecific inhibitor of HIV proteinase Ro 31–8959 on virus maturation in a chronically infected promonocytic cell line (CD. Antiviral Chem. Chemother. (1991) 2:181–186.
   Google Scholar
• WEISS RA: How does Illy cause AIDS? Science (1993)260:1273–1279.
   PubMed Web of Science ®Google Scholar
• HOLMES HC, MAHMOUD N, KARPAS A, PETRIK J, KINCH-INGTON D, O'CONNOR T, JEFFRIES DJ, DESMYTER J, DE CLERCQ E, PALWELS R, HAY A: Screening of compounds for activity against HIV: a collaborative study. Antiviral Chem. Chemot her. (1991) 2:287–293.
   Google Scholar
• JOHNSON VA, MERRILL DP, CHOU T-C, HIRSCH MS: Hu-man immunodeficiency virus type-1 (111V-1) inhibitory Interactions between protease inhibitor Ro 31–8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant in-terferon-alpha-A against zidovudine-sensitive and -re-sistant 111V-1 in vitro. J. Infect. Dis. (1992) 166:1143-1146. Data on the potential for synergy with other agents.
   Google Scholar
• GAO WY, SHIRASAKA T, JOHNS DG, BRODER S, MITSUYA H: Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. (1993) 91:2326–2333.
   PubMed Web of Science ®Google Scholar
• ANTONELLI G, TURRIZIANI 0,CIANFRIGLIA M, RIVA E,DONG G. FATTOROSSIANZANI F: Resistance of HIV-1 to AZT might also involve the cellular expression of mul-tidrug resistance P-glycoprotein. AIDS Res. Hum. Retroviruses (1992) 8:1839–1843.
   Google Scholar
• DIANZANI F. ANTONELLI G, TURRIZIANI 0, RIVA E,SIMEONI E, SIGNORETTI C, STROSSELLI S, CIANFIGLIA M: Zidovudine induces the expression of cellular resis-tance affecting its antiviral activity. AIDS Res. Hum. Retroviruses (1994) 10:1471–1478.
   PubMed Web of Science ®Google Scholar
• ILELLO JA, BILELLO PA, PRITCHARD M, ROBINS T,DRUSANO GL: Reduction of the in vitro activity of A77003, an inhibitor of human inamunodeficiency vi-rus protease, by serum al acid glycoprotein. J. Infect. Dis. (1995) 171:546–551.
   Google Scholar
• PERNO CF, AQUARO 5, ROSENWIRTH B, I3ALESTRA E,PEICHL P, BILLICI I A, VILLANI N, CALIO R: In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J. Leukocyte Biol. (1994) 56:381–386.
   PubMed Web of Science ®Google Scholar
• ROOT M, KEET IP, VOS AH, DE GOEDE RE, ROOS MT, COUTINHO RA MIEDEMA F, SCHELLEKENS PT, TERS-METTE M: Prognostic value of 111V-1 syncytiuna-induc-ing phenotype for rate of CD4 cell depletion and progression to AIDS. Ann. Intern. Med. (1993) 118 :681–688 .
   PubMed Web of Science ®Google Scholar
• MACATONIA SE, DUNCAN IB, KNIGIIT SC: Improved function of dendritic cells exposed in vitro to human immuno-deficiency virus type 1 (111V-1) on treatment with the proteinase inhibitor Ro 31–8959.
   Google Scholar
• Nth Interna-tional Conference on AIDS'. Berlin (1993). Abstract Po-A25-0601. MACATONIA SE. GOMPELS M, PINCHING AL KNIGHT SC: Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology (1990) 7138–15.
   Google Scholar
• NITSCHKOLINT)HOFEIZ LI. SCHAETZI. 11. EBERLE J. 1)EBY G. KRANZ B. VON DER I TELM K: Long-term treat- ment of HIV-infected MT-4 cells in culture with HIV proteinase inhibitor Ro 31–8959 leads to complete cure of infection_ Antiviral Chem. Chemother. (1994) 5:236–242.
   Google Scholar
• CRAIG JC, WHITTAKER LN, DUNCAN TB. ROBERTS NA: In vitro anti-11W and cytotoxicological evaluation of the triple combination: AZT and zalcitabine with HIV pro-teinase inhibitor saquinavir (Ro 31–8959). Antiviral Chem. Chemotber. (1994) 5:380–386.
   Google Scholar
• GALPIN S, ROBERTS NA, O'CONNOR T: Antiviral proper-ties of the HIV-1 proteinase inhibitor Ro 31–8959. An-tiviral Chem. Chemother. (1994) 5:43-45. Up-to-date review of in vitro data on saquinavir.
   Google Scholar
• CRAIG JC, WHITTAKER LN, DUNCAN TB, ROBERTS NA: In vitro resistance to an inhibitor of my proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TWO). Antiviral Chem. Chem other, (1993) 4:335–339.
   Web of Science ®Google Scholar
• DIANZANI F, ANTONELLI G, TURRIZIANI 0, RIVA E, DONGG, BELLAROSA D: In vitro selection of human immu-nodeficiency virus type 1 resistant to Ro 31-8959 prote-inase inhibitor. Antiviral Chem. Chemother, (1993) 4:329–333.
   Google Scholar
• PAUWELS R, ANDRIES K, DESMYTER J, SCHOLS D, KUKLAMJ, BRESLIN HJ, RAEYMAECKERS A, VAN GELDER J, WOESTENBORGHS R, HEYKANTS J, SCHELLEKENS K, JANSSEN MAC, DE CLERQ E, JANSSEN PAJ: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 343:470–474.
   PubMed Web of Science ®Google Scholar
• JOHNSON VA, MERRILL DP, VIDELER JA, CHOU TC, BY-ING TON RE, ERON JJ, D'AQUILA RT, HIRSCH MS: Two-drug combinations of zidovudine, didanosine, and recombi-nant interferon inhibit replication of zidovudine-resis-tant human immunodeficiency virus type-1 synergistically in vitro. J. Infect. Dis. (1991) 64:646–655.
   Google Scholar
• VELLA S, BUTTO S, FRANCO M, OLIVETTA E, TOMINO C,GALLUZZO C, GIANNINI G, PIRILLO MF, JACOBSEN H, MOUS J, DUNCAN TB, SARMATI L, ERCOLI L, ANDREONI M: Viral load and CD4* responses during combination therapy with zidovudine and saquinavir: correlation with the emergence of viral isolates with reduced sen-sitivity 4th International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 43.
   Google Scholar
• JACOBSEN H, YASARGIL K, WINSLOW DL, CRAIG JC, •KROHN A. DUNCAN TB, MOUS ji Characterisation ofhuman immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31–8959. Virology (1995) 206:527-534. Important evaluations of clinical isolates and resistance to saquinavir.
   Google Scholar
• JACOBSEN H, HAENGGI M, OTT M, DUNCAN TB, MOUS J: Resistance to saquinavir: update of the genotypic analy-sis of Phase n trials. 35th ICAAC San Francisco (1995) Abstract 1174.
   Google Scholar
• JACOBSEN II, HAENGGI M, OTT M. DUNCAN TB, AN-DREONI M, VELLA 5, MOUS Ji Reduced sensitivity of saquinavir: an update on genotyping from Phase I/11 trials. 4th International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 68.
   Google Scholar
• KROHN A. REDSHAW S, RICHIE JC, GRAVES BJ, I IATADAMil: Novel binding mode of highly potent HIV-protei-nase inhibitors incorporating the (R)-hydroxyethyl-amine isostere. J. Med. Chem (1991) 34:3340–3342.
   PubMed Web of Science ®Google Scholar
• EBERLE J, BECHOWSKY B, ROSE D, HAUSER U, VON DER HELM K, GURTLER L, NITSCHKO H: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses (1995) 6:671–676.
   Google Scholar
• SHAPIRO JM, WINTERS MA, KOZA_L MJ, MERIGAN TC: •Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage. 35th ICAAC. San Francisco (1995). Abstract LB-5. First clinical data at higher drug exposures.
   Google Scholar
• MELLORS JW, LARDERBA, SCIIINAZI RE: Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News (1995) 3:8–13.
   Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM, GABRYELSKI LJ, •GRAHAM DJ, QUINTERO JC, RHODES A, ROBBINS HL,ROTH E, SHIVAPRAKASH M, TITUS D, YANG T, TEPPLER H, SQUIRES KB, DEUTSCH PJ, EMINI EA: In vivo emer-gence of MV-1 variants resistant to multiple protease inhibitors. Nature (1995) 374:569-571, Important paper raising concerns of cross-resistant virus being selected for during indinavir monotherapy.
   Google Scholar
• NORBECK D, KUMAR G, MARSH K, RODRIGUES D, MCDONALD E, MOLLA A, DENISSEN J, KEMPF D, LEONARD J: Ritonavir and saquinavir: potential for two-dimen-sional synergy between IHV protease inhibitors. 35th ICAAC. San Francisco (1995). Abstract LB–7.
   Google Scholar
• WILSON SI, PHYLIP LH, MILLS JS, DUNN BM, KAY J: Interactions of substrates and inhibitors with escape mutants of HIV-1 proteinase. 4th International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 66.
   Google Scholar
• CONNELL EV, IISU MC, RICHMAN DD: Combinative inter-actions of a human immunodeficiency virus (HIV) tat antagonist with HIV reverse transcriptase inhibitors and an HIV proteinase inhibitor. Antimicrob. Agents Chemother. (1994) 38:348–352.
   PubMed Web of Science ®Google Scholar
• WILLIAMS PEO, MUIRHEAD GJ, MADIGAN MJ: Dispositionand bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br./ Clin. Pharmacol. (1992) 34:155–156.
   Google Scholar
• SHAW TM, MUIRHEAD GJ, PARISH N: Tolerability andphartnacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor. Br.]. Clin. Pharmacol. (1992) 34:166–167.
   Google Scholar
• TIIE /IIV PROTEASE PROJECT TEAM: Comparison of thein vitro antiviral activity and preliminary pharmacoki-netics in mice of the HIV-1 protease inhibitors, CGP 53437 and Ro 31–8959. 33rd ICAAC. New Orleans (1993). Abstract.
   Google Scholar
• FAHEY J, TAYLOR JM, DETELS R, HOFMANN B, MELMEDR. NISHANIAN P. GIORGI JV: The prognostic value of cellular and serologic markers in infection with human itcununodeficiency virus type 1. New Engl, J. Med. (1990) 322:166–172.
   Google Scholar
• JACOBSON MA, BACCHEITI P, KOLOKATHIS A, CI IAISSONRE, SZABO S, POLSKY B, VALAINIS GT, MILDVAN D, ABRAMS D, WILBER J, WINGER E, SACKS HS, HENDRICK-SEN C, MOSS A: Surrogate markers for survival in pa-tients with AIDS and AIDS-related complex treated with zidovudine. Br. Med.]. (1991) 302:73–78.
   PubMed Web of Science ®Google Scholar
• EASTERBROOK PJ, EMAMI J, MOYLE G, GAZZAR.D B: Progressive CD4 depletion and death in zidovudine-treated patients.]. AIDS (1993) 6:927–929.
   Google Scholar
• GRAHAM NM, PIANTADOSI S, PARK LP, PHAIR JP, RI-NALDO CR, FAHEY JL: CD4'" lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J. AIDS (1993) 6:1258–1266.
   PubMed Web of Science ®Google Scholar
• CHOI S, LAGAKOS SW, SCHOOLEY RT, VOLBERDING PA:CD4* lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann. Int. Med. (1993) 118:674–680.
   PubMed Web of Science ®Google Scholar
• DEGRUTTOLA V, WULFSOHN M, FISCHL M, TSIATIS A: Modeling the relationship between survival and CD4' lymphocytes in patients with AIDS and AIDS-related complex.]. AIDS (1993) 6:359–365.
   PubMed Web of Science ®Google Scholar
• COOMBS RW: HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS. Clin. Lab. Med. (1994) 14:301–311.
   PubMed Web of Science ®Google Scholar
• KITCHEN VS, SKINNER C, ARIYOSHI K, LANE EA, DUNCAN TB, BURCKHARDT J, BURGER HU, BRAGMAN K, PINCHING AJ, WEBER JN: Safety and activity of saquinavir in HIV infection. Lancet (1999 345:952–955.
   Google Scholar
• DELFRAISSY, JF, SERINI D, BRUN-VEZINET F, DUSSALX E, KIRVINE A, DORMONT J, BRAGMAN K: A Phase I-II dose ranging study of the safety and activity of Ro 31–8959 (HIV-proteinase inhibitor) in previously zidovudine (zidovudine) treated HIV-infected individuals. Nth In-ternational Conference on AIDS. Berlin (1993). Abstract WS-B26-3. With 1621, first clinical monotherapy studies.
   Google Scholar
• VELLA S: Update on a proteinase inhibitor. AIDS (1994) 89\(Suppl. 3):S25–S29.
   Google Scholar
• COLLIER AC, COOMBS RW, SCHOENFELD DA, BASSETT R, •BARUCH A, COREY L: Extended treatment with saqui-navir (SAQ), zidovudine (zidovudine), and zalcitabine (zalcitabine)vs. SAQ and zidovudine vs. zakitabine and zidovudine. 35th ICAAC. San Francisco (1995). Abstract 1173.
   Google Scholar